ReviewNeuropsychiatric disease and treatment2019
Transcranial Photobiomodulation For The Management Of Depression: Current Perspectives.
Review in Neuropsychiatric disease and treatment, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04404231 (Treatment of Intrapartum Depression Using Non-invasive Photobiomodulation), which is not on this map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment of Intrapartum Depression Using Non-invasive Photobiomodulation
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Transcranial Photobiomodulation on Depressive Symptoms: A Meta-Analysis.Photobiomodulation, photomedicine, and laser surgery · 2023Pooled it
- Trial
- Transcranial photobiomodulation with near-infrared laser induces analgesia in rats.The Journal of physiology · 2026Article
- Molecular Mechanisms of Emerging Antidepressant Strategies: From Ketamine to Neuromodulation.International journal of molecular sciences · 2025Review
- Transcranial photobiomodulation promotes traumatic brain injury recovery via modulating glial cell polarization and neuroinflammation: a study of 1064 nm light-emitting diodes.Journal of translational medicine · 2025Article
- Innovative approaches in the treatment-resistant depression: exploring different therapeutic pathways.GeroScience · 2025Review
- Personalized Repetitive Transcranial Magnetic Stimulation (PrTMSActa scientific neurology · 2025Article
- Efficacy and safety of laser acupuncture for treating insomnia in major depressive disorder: study protocol for a randomized controlled trial.Frontiers in psychiatry · 2025Article
- Transcranial Irradiation Mitigates Paradoxical Sleep Deprivation Effect in an Age-Dependent Manner: Role of BDNF and GLP-1.Neurochemical research · 2024Article
- Opportunities and obstacles in non-invasive brain stimulation.Frontiers in human neuroscience · 2024Article
- Transcranial photobiomodulation in children aged 2-6 years: a randomized sham-controlled clinical trial assessing safety, efficacy, and impact on autism spectrum disorder symptoms and brain electrophysiology.Frontiers in neurology · 2024Article
- A novel transcranial photobiomodulation device to address motor signs of Parkinson's disease: a parallel randomised feasibility study.EClinicalMedicine · 2023Article
- Whole-Body Photobiomodulation Therapy for Fibromyalgia: A Feasibility Trial.Behavioral sciences (Basel, Switzerland) · 2023Article
- Neuroinflammation mechanisms of neuromodulation therapies for anxiety and depression.Translational psychiatry · 2023Review
- Article
- Therapeutic non-invasive brain treatments in Alzheimer's disease: recent advances and challenges.Inflammation and regeneration · 2022Review
- Transcranial Photobiomodulation for the Treatment of Children with Autism Spectrum Disorder (ASD): A Retrospective Study.Children (Basel, Switzerland) · 2022Article
- Photobiomodulation prevents PTSD-like memory impairments in rats.Molecular psychiatry · 2021Article
- Effects of prenatal photobiomodulation treatment on neonatal hypoxic ischemia in rat offspring.Theranostics · 2021Article
- Defining Surgical Terminology and Risk for Brain Computer Interface Technologies.Frontiers in neuroscience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a prevalent condition associated with high rates of disability, as well as suicidal ideation and behavior. Current treatments for MDD have significant limitations in efficacy and side effect burden. FDA-approved devices for MDD are burdensome (due to repeated in-office procedures) and are most suitable for severely ill subjects. There is a critical need for device-based treatments in MDD that are efficacious, well-tolerated, and easy to use. In this paper, we review a novel neuromodulation strategy, transcranial photobiomodulation (t-PBM) with near-infrared light (NIR). The scope of our review includes the known biological mechanisms of t-PBM, as well as its efficacy in animal models of depression and in patients with MDD. Theoretically, t-PBM penetrates into the cerebral cortex, stimulating the mitochondrial respiratory chain, and also significantly increases cerebral blood flow. Animal and human studies, using a variety of t-PBM settings and experimental models, suggest that t-PBM may have significant efficacy and good tolerability in MDD. In aggregate, these data support the need for large confirmatory studies for t-PBM as a novel, likely safe, and easy-to-administer antidepressant treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.